TECHNOLOGY OF CINEMATIC ARCHITECTURE IN SCIENCE FICTION MOVIES

Cinematic architecture in the broadest terms, portrayed spaces as a scene, where it conceives and reads the built environment in terms of sequences. It explores the effect of futuristic architecture and highlight the significant role of cinematic architecture in the society. Both movies and architecture function as languages, with two components: the signifiers, which are the tangible forms of signs, and the signified, which are the concepts, thoughts, and ideals that the signifiers contain. Unfortunately, the world is experiencing fast changes as a result of the massive rise of technology and capitalism, and the cinema industry plays an important role in displaying these improvements, showing the up - coming future through various science fiction movies, that either operate as an alert system for transformation, with the majority of these depictions viewing futuristic architecture and urban design as a dystopian realm, a lack of how to manage the upcoming issues, and these visions may come to pass. This paper aims to recognize different technological approaches to create the cinematic architecture, presented in the science fiction movies. To achieve this aim, the paper will start with literature review, based on desk research, reviewing previous readings, then the paper will analyze two case studies, which are the Movie of Tron Legacy, 2010, and the Avatar movie, James Cameron, 2009. As a conclusion, a better understanding the link between movie and architecture, it may be a better convey the complex concepts and ambitions for cities through architectural elements and signifiers

Candida parapsilosis Characterization in an Outbreak Setting

Candida parapsilosis is an important non-albicans species which infects hospitalized patients. No studies have correlated outbreak infections of C. parapsilosis with multiple virulence factors. We used DNA fingerprinting to determine genetic variability among isolates from a C. parapsilosis outbreak and from our clinical database. We compared phenotypic markers of pathogenesis, including adherence, biofilm formation, and protein secretion (secretory aspartic protease [SAP] and phospholipase). Adherence was measured as colony counts on silicone elastomer disks immersed in agar. Biofilms formed on disks were quantified by dry weight. SAP expression was measured by hydrolysis of bovine albumin; a colorimetric assay was used to quantitate phospholipase. DNA fingerprinting indicated that the outbreak isolates were clonal and genetically distinct from our database. Biofilm expression by the outbreak clone was greater than that of sporadic isolates (p < 0.0005). Adherence and protein secretion did not correlate with strain pathogenicity. These results suggest that biofilm production plays a role in C. parapsilosis outbreaks

Aspergillus endocarditis 2003-2009

A retrospective study of 35 case reports of Aspergillus endocarditis published between 2003 and 2009 was carried out. Fifteen percent of cases presented with a new cardiac murmur, 38% with an embolus. Eighty percent of cases involved the aortic or mitral valves. Seventy-four percent of cases involved patients with a history of prior surgery, 48% of these involved a heart valve, 20% had other cardiac surgery and 32% had non-cardiac surgery. Galactomannan testing was helpful diagnostically in four out of nine cases, but PCR testing was positive in six out of six cases. Overall mortality was 68%, all eight survivors had heart valve surgery apart from one – an 8-month-old child. Seven out of eight survivors received liposomal amphotericin B, three of these in combination with other antifungals. We need to think more about the possibility of Aspergillus endocarditis, particularly in immunocompromised patients with recent surgery. Galactomannan and PCR testing may be used more vigorously. Valve replacement, or at least vegetectomy, should be carried out in all patients. Liposomal amphotericin B, 3–5mg/kg/day, for at least 4 weeks is the treatment of choice. Oral voriconazole should be used for at least 2 years. Posaconazole may be an alternative, however there have been no prior cases reported to suggest its efficacy. The value of combination antifungal therapy is uncertain, but consideration should be given to the use of a second agent in addition to liposomal amphotericin. While further case reports on this condition will be helpful, more definitive management guidelines will depend on a prospective study

Activity of phenolic compounds from plant origin against Candida species

Candida albicans and other Candida species have been highly associated with several opportunistic fungal infections. Their ability to develop host infections is incited by different determinants, being virulence factors the most highlighted. Molecular targets of the antifungal drugs are crucial components for determination of yeast survival. Ergosterol, nucleic acids and glucan are the most studied molecular targets to destroy Candida species, being considered the basis of the development of new antifungal drugs. However, increasing levels of resistant Candida species to the current antifungal drugs have been observed, making ineffective those agents. Thus, other therapies more effective and safer than the current ones, are being studied, namely the use plant of extracts enriched in phenolic compounds. In this sense, this manuscript provide an historical perspective of the opportunistic fungal infections, molecular targets of the current anti-Candida drugs, as well as a general description of the active principles present in plants, focused on the antifungal potential of whole plant extracts and isolated phenolic compounds, against Candida species.Foundation for Science and Technology (FCT, Portugal) grant (SFRH/BD/87658/2012), “Programa Compromisso com Ciência – 2008” and financial support to the Research Centre CIMO (strategic project PEst-OE/AGR/UI0690/2011). This work was also supported by the Programa Operacional, Fatores de competitividade – COMPETE and by national funds through FCT – Fundação para a Ciência e a Tecnologia on the scope of the projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012 and PEst-OE/EQB/LA0023/2013. Project “BioHealth – Biotechnology and Bioengineering approaches to improve health quality”, Ref. NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional do Norte (ON.2-O Novo Norte), QREN, FEDER